X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Patients need to pay less for their medicines. States can help.

By Scott LaGanga  |    January 26, 2022
No one should struggle to afford the medicines they need. Unfortunately, some patients continue to bear more of their medicine costs at the pharmacy counter. Patients with deductibles have seen...   Read More

It’s a new year, but sadly Congress is still pursuing flawed price setting policies

By Nicole Longo  |    January 25, 2022
As we kick off 2022, Congress has a number of priorities they are aiming to tackle, including the Build Back Better Act (BBBA). Unfortunately, the bill includes policies that would take the...   Read More

New poll of all 50 states and 435 Congressional Districts shows perils of so-called Medicare “negotiation”

By Cynthia Hicks  |    January 25, 2022
A new large-scale survey of 20,000 Americans covering all states and Congressional districts shows a majority find health care coverage costs unreasonable and a top priority health care issue for...   Read More

CBO reaffirms our innovation ecosystem leads to improved lives, long-term savings

By Brian Newell  |    January 21, 2022
The Congressional Budget Office (CBO) recently released a new report looking at trends in spending, prices and use of prescription drugs. While some politicians are trying to use the report to...   Read More

New study finds more than half of brand medicine spending goes to the supply chain and others

By Brian Newell  |    January 7, 2022
More than half of total spending on brand medicines went to the supply chain, middlemen and other stakeholders in 2020 according to a new analysis from the Berkeley Research Group (BRG). These new...   Read More

Making medicines more affordable: Preserving safety-net programs like 340B

By Emilie Signora  |    December 17, 2021
Common-sense reforms can help ensure everyone benefits from America’s engine of innovation and receives the care they need and deserve. In this series, we’re taking a closer look at PhRMA’s...   Read More

Post-approval research save lives. Why is Congress trying disincentivize it?

By Andrew Powaleny  |    December 17, 2021
While some in Congress continue to claim the latest drug pricing plan in Washington is “negotiation,” that is far from the truth. The reality is that the current plan gives the government a new...   Read More

A price control by any other name would still put patients at risk and threaten innovation

By Nicole Longo  |    December 9, 2021
Some policymakers in DC are laser focused on giving the government the power to “negotiate” in Medicare. What they aren’t saying is that this isn’t negotiation at all. They essentially just want...   Read More

Making medicines more affordable: Making insurance work like insurance

By Emilie Signora  |    December 8, 2021
Common-sense reforms can help ensure everyone benefits from America’s engine of innovation and receives the care they need and deserve. In this series, we’re taking a closer look at PhRMA’s...   Read More

3 things to know about the importance of post-approval research and development

By Andrew Powaleny  |    December 6, 2021
Despite tremendous progress and knowledge gained from post-approval R&D, some in Congress still fail to recognize innovation doesn’t stop at U.S. Food and Drug Administration (FDA) approval. After...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates